Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhi-Fu Tao

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|February 14, 2015
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
ACS Medicinal Chemistry Letters|June 20, 2014
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XLMichael F T Koehler, Philippe Bergeron, Edna F Choo, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
Molecular Cancer Therapeutics|March 31, 2021
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
ACS Medicinal Chemistry Letters|October 15, 2014
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.
Science Advances|October 4, 2024
BCL-X<sub>L</sub>-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|February 14, 2015
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
ACS Medicinal Chemistry Letters|June 20, 2014
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XLMichael F T Koehler, Philippe Bergeron, Edna F Choo, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
Molecular Cancer Therapeutics|March 31, 2021
Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy VolunteersAhmed Hamed Salem, Zhi-Fu Tao, Orlando F Bueno, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
ACS Medicinal Chemistry Letters|October 15, 2014
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo ActivityZhi-Fu Tao, Lisa Hasvold, Le Wang, et al.
Science Advances|October 4, 2024
BCL-X<sub>L</sub>-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.
Pageof 4